Real‐world effectiveness of azvudine: Elixir or equivocal answer?

Journal of Medical VirologyVolume 95, Issue 7 e28940 LETTER TO THE EDITOR Real-world effectiveness of azvudine: Elixir or equivocal answer? Yuan Gao, Yuan Gao orcid.org/0000-0002-0670-9104 Fourth Department of Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorZujin Luo, Zujin Luo Department of Respiratory and Critical Care Medicine, Beijing Engineering Research Center of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorZhongjie Hu, Corresponding Author Zhongjie Hu [email protected] Liver Disease Center, Beijing You'An Hospital, Beijing, China Correspondence Zhongjie Hu, Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected] Yingmin Ma, Department of Respiratory and Critical Care Medicine, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected]Search for more papers by this authorYingmin Ma, Corresponding Author Yingmin Ma [email protected] Department of Respiratory and Critical Care Medicine, Beijing You'An Hospital, Capital Medical University, Beijing, China Correspondence Zhongjie Hu, Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected] Yingmin Ma, Department of Respiratory and Critical Care Medicine, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected]Search for more papers by this author Yuan Gao, Yuan Gao orcid.org/0000-0002-0670-9104 Fourth Department of Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorZujin Luo, Zujin Luo Department of Respiratory and Critical Care Medicine, Beijing Engineering Research Center of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorZhongjie Hu, Corresponding Author Zhongjie Hu [email protected] Liver Disease Center, Beijing You'An Hospital, Beijing, China Correspondence Zhongjie Hu, Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected] Yingmin Ma, Department of Respiratory and Critical Care Medicine, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected]Search for more papers by this authorYingmin Ma, Corresponding Author Yingmin Ma [email protected] Department of Respiratory and Critical Care Medicine, Beijing You'An Hospital, Capital Medical University, Beijing, China Correspondence Zhongjie Hu, Liver Disease Center, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected] Yingmin Ma, Department of Respiratory and Critical Care Medicine, Beijing You'An Hospital, Capital Medical University, Beijing 100069, China. Email: [email protected]Search for more papers by this author First published: 05 July 2023 https://doi.org/10.1002/jmv.28940 Yuan Gao and Zujin Luo contributed equally. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Deng G, Li D, Sun Y, et al. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J Med Virol. 2023; 95(4):e28756. 2Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023; 95(4):e28732. 3Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022; 386(15): 1397- 1408. 4Cheema HA, Jafar U, Sohail A, et al. Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023; 95(2):e28471. 5Gao Y, Luo Z, Ren S, et al. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19. J Infect. 2023; 86(6): e158- e160. 6da Silva RM, Gebe Abreu Cabral P, de Souza SB, et al. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med. 2023; 10:1143485. 7Zhang JL, Li YH, Wang LL, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021; 6(1): 414. 8 Center for Drug Evaluation. 2022. Azvudine tablets (CXHS2000016-17) package insert. https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=e8ce9d77fb0456c7eaf6f1c025040cb7 9Pan Y, Wang L, Feng Z, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet. 2023; 401(10377): 664- 672. 10 National Medical Products Administration. 2023. China grants conditional approval for two homegrown COVID-19 drugs. http://english.www.gov.cn/statecouncil/ministries/202301/29/content_WS63d671e4c6d0a757729e624f.html Volume95, Issue7July 2023e28940 ReferencesRelatedInformation